Evidence map›Paper›PMID 36401282›Full record

ReviewJournal of translational medicine2022

Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.

Ajaz A Bhat, Sabah Nisar, Soumi Mukherjee, Nirmalya Saha, Nageswari Yarravarapu, Saife N Lone, Tariq Masoodi, Ravi Chauhan, Selma Maacha, Puneet Bagga and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Role of the STAT3 Signaling Pathway in Cell Proliferation and Inflammation in Psoriasis and Approaches for Targeted Therapies: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ajaz A Bhat *Department of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Sabah Nisar *Department of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Soumi Mukherjee *Saha Institute of Nuclear Physics Complex (MSA-II), Kolkata, West Bengal, India.
Nirmalya Saha *Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Nageswari Yarravarapu *Vector Laboratories, Inc, 6737 Mowry Ave, Newark, CA, 94560, USA.
Saife N LoneDepartment of Biotechnology, School of Life Sciences, Central University of Kashmir, Ganderbal, Jammu & Kashmir, India.
Tariq MasoodiLaboratory of Cancer Immunology and Genetics, Sidra Medicine, Doha, Qatar.
Ravi ChauhanDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Selma MaachaDepartment of Surgery, Miller School of Medicine, University of Miami, Rosenstiel Med Science Bldg., 1600 NW 10Th Ave, Room 4007, Miami, FL, 33136-1015, USA.
Puneet BaggaDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA.
Punita DhawanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Ammira Al-Shabeeb AkilDepartment of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Wael El-RifaiDepartment of Surgery, Miller School of Medicine, University of Miami, Rosenstiel Med Science Bldg., 1600 NW 10Th Ave, Room 4007, Miami, FL, 33136-1015, USA.
Shahab UddinTranslational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Ravinder ReddyCenter for Advanced Metabolic Imaging in Precision Medicine, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Mayank SinghDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India. mayank.osu@gmail.com.
Muzafar A MachaWatson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Jammu & Kashmir, India. muzafar.aiiims@gmail.com.
Mohammad HarisLaboratory Animal Research Center, Qatar University, Doha, Qatar. Mohammad.Haris@pennmedicine.upenn.edu.ORCID 0000-0002-4945-2935

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene editing has great potential in treating diseases caused by well-characterized molecular alterations. The introduction of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-based gene-editing tools has substantially improved the precision and efficiency of gene editing. The CRISPR/Cas9 system offers several advantages over the existing gene-editing approaches, such as its ability to target practically any genomic sequence, enabling the rapid development and deployment of novel CRISPR-mediated knock-out/knock-in methods. CRISPR/Cas9 has been widely used to develop cancer models, validate essential genes as druggable targets, study drug-resistance mechanisms, explore gene non-coding areas, and develop biomarkers. CRISPR gene editing can create more-effective chimeric antigen receptor (CAR)-T cells that are durable, cost-effective, and more readily available. However, further research is needed to define the CRISPR/Cas9 system's pros and cons, establish best practices, and determine social and ethical implications. This review summarizes recent CRISPR/Cas9 developments, particularly in cancer research and immunotherapy, and the potential of CRISPR/Cas9-based screening in developing cancer precision medicine and engineering models for targeted cancer therapy, highlighting the existing challenges and future directions. Lastly, we highlight the role of artificial intelligence in refining the CRISPR system's on-target and off-target effects, a critical factor for the broader application in cancer therapeutics.

Indexed as

CRISPR-Cas SystemsNeoplasmsArtificial IntelligenceGene EditingHumansImmunotherapyArtificial intelligenceCancer biomarkerCancer ImmunotherapyCancer precision medicineCAR T-cellsCRISPR/Cas9Drug resistanceEpigeneticsGenome engineering

Identifiers

PMID36401282
PMCPMC9673220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.